Omada Health (OMDA) Valuation Check As GAAP Profitability And GLP 1 Flex Care Launch Draw Fresh Attention

Simply Wall St.

Mar 09

Omada Health (OMDA) is back in focus after reporting its first GAAP profitable quarter, alongside revenue growth in 2025 and improved margins, while also rolling out its GLP-1 Flex Care program for ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2618627124"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618627124\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618627124?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957","is_english":true,"pubTime":"2026-03-09 21:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618627124","market":"us","top_or_hot":-1,"title":"Omada Health (OMDA) Valuation Check As GAAP Profitability And GLP 1 Flex Care Launch Draw Fresh Attention","media":"Simply Wall St.","content":"<div>\n<p>Omada Health (OMDA) is back in focus after reporting its first GAAP profitable quarter, alongside revenue growth in 2025 and improved margins, while also rolling out its GLP-1 Flex Care program for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omda/omada-health/news/omada-health-omda-valuation-check-as-gaap-profitability-and\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Omada Health (OMDA) Valuation Check As GAAP Profitability And GLP 1 Flex Care Launch Draw Fresh Attention</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOmada Health (OMDA) Valuation Check As GAAP Profitability And GLP 1 Flex Care Launch Draw Fresh Attention\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-09 21:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nasdaq-omda/omada-health/news/omada-health-omda-valuation-check-as-gaap-profitability-and><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Omada Health (OMDA) is back in focus after reporting its first GAAP profitable quarter, alongside revenue growth in 2025 and improved margins, while also rolling out its GLP-1 Flex Care program for ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nasdaq-omda/omada-health/news/omada-health-omda-valuation-check-as-gaap-profitability-and\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLP","symbol_name":"Global Partners Lp","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omda/omada-health/news/omada-health-omda-valuation-check-as-gaap-profitability-and","article_id":"2618627124","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice1-main-header/1585186661957"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-omda/omada-health/news/omada-health-omda-valuation-check-as-gaap-profitability-and","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2618627124","pubTimestamp":1773062528,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Omada Health (OMDA) is back in focus after reporting its first GAAP profitable quarter, alongside revenue growth in 2025 and improved margins, while also rolling out its GLP-1 Flex Care program for employers.\nSee our latest analysis for Omada Health.\nThe recent earnings beat, first GAAP profitable quarter and launch of GLP-1 Flex Care have coincided with a 20.6% 1 month share price return. However, the negative 90 day and year to date share price returns suggest momentum has only recently...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLP":"Global Partners Lp","OMDA":"Omada Health","BK4144":"石油与天然气的储存和运输","BK4196":"保健护理服务","BK4590":"PTP"},"translate_title":"随着GAAP盈利能力和GLP 1 Flex Care的推出引起新的关注，Omada Health(OMDA)估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OMDA":1.5,"GLP":1.5},"content_text":"Omada Health (OMDA) is back in focus after reporting its first GAAP profitable quarter, alongside revenue growth in 2025 and improved margins, while also rolling out its GLP-1 Flex Care program for employers. See our latest analysis for Omada Health. The recent earnings beat, first GAAP profitable quarter and launch of GLP-1 Flex Care have coincided with a 20.6% 1 month share price return. However, the negative 90 day and year to date share price returns suggest momentum has only recently started to build from a weaker base. If this GLP-1 themed news has your attention, it could be a good moment to see what else is moving in healthcare AI, starting with our list of 32 healthcare AI stocks. With the shares at US$14.05 and trading at a discount to both analyst targets and some intrinsic value estimates, the key question now is whether Omada Health is still mispriced or if the market is already banking on future growth. AdvertisementMost Popular Narrative: 51.4% Undervalued With Omada Health last closing at $14.05 against a most popular fair value narrative of $28.90, the valuation debate is really about what future growth and margins could look like if the business hits its targets under that story.  Scaling GLP-1 prescribing alongside the existing GLP-1 Care Track positions Omada as a key coordinator for rapidly expanding obesity therapies, supporting higher average revenue per member and sustained revenue growth.  Read the complete narrative. Curious what kind of revenue ramp and margin shift would need to sit behind that fair value? This narrative leans on fast top line expansion, a meaningful swing in profit margins and a future earnings multiple that is usually associated with high growth leaders. The full breakdown shows how those pieces fit together without leaving the numbers to guesswork. Result: Fair Value of $28.90 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, this story can change quickly if Omada’s bigger 2026 investment push fails to earn its keep or if GLP-1 coverage and demand shift against it. Find out about the key risks to this Omada Health narrative. Another Angle: Multiples Paint a Tighter Picture That 51.4% undervalued fair value story sits next to a less generous signal. On a price-to-sales ratio of 3.2x, Omada Health trades above both the Healthcare industry at 1.3x and the peer average at 1.9x, and even above a fair ratio of 3x. This suggests there may be less room for error if growth or margins disappoint. See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:OMDA P/S Ratio as at Mar 2026Next Steps If this mix of upside potential and tighter valuation has you thinking, it is worth checking the details for yourself and moving quickly to shape your own view. You can start with the company’s 3 key rewards. Looking for more investment ideas? If Omada has sharpened your focus, do not stop here. Use the screener to quickly surface other opportunities that might fit your style before the crowd catches on.  Target potential value opportunities by scanning our list of 50 high quality undervalued stocks that pair stronger fundamentals with prices below some estimates of fair worth. Strengthen your income stream by reviewing 16 dividend fortresses, where yields above 5% come with an emphasis on stability. Get ahead of the crowd by checking our screener containing 24 high quality undiscovered gems, highlighting quality companies that are not yet widely followed.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}